Drug Profile
Research programme: bone disorder therapeutics - Enzo Therapeutics/University of Conneticut
Alternative Names: Enzo D58; IIIC3Latest Information Update: 30 Sep 2009
Price :
$50
*
At a glance
- Originator Enzo Therapeutics; University of Connecticut
- Class Small molecules
- Mechanism of Action Osteogenesis stimulants; Signal transduction pathway modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bone disorders; Periodontal disorders